Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Sun Och Yoon
Histiocytic and dendritic cell neoplasms comprise diverse tumors originating from the mononuclear phagocytic system, which includes monocytes, macrophages, and dendritic cells. The 5th edition of the World Health Organization (WHO) classification updating the categorization of these tumors, reflecting a deeper understanding of their pathogenesis.In this updated classification system, tumors are categorized as Langerhans cell and other dendritic cell neoplasms, histiocyte/macrophage neoplasms, and plasmacytoid dendritic cell neoplasms...
May 7, 2024: Blood Research
#2
JOURNAL ARTICLE
Denis Nchang Che, NaHye Lee, Hyo-Jung Lee, Yea-Won Kim, Solongo Battulga, Ha Na Lee, Won-Kook Ham, Hyunah Lee, Mi Young Lee, Dawoon Kim, Haengji Kang, Subin Yun, Jinju Park, Daeyoun David Won, Jong Kyun Lee
PURPOSE: Colorectal cancer (CRC) is the most frequent cancer with limited therapeutic achievements. Recently, adoptive cellular immunotherapy has been developed as an antitumor therapy. However, its efficacy has not been tested in CRC. This study investigated the ability of an immune cell cocktail of dendritic cells (DCs), T cells, and natural killer (NK) cells to overcome immunological hurdles and improve the therapeutic efficacy of cell therapy for CRC. METHODS: CRC lysate-pulsed monocyte-derived DCs (Mo-DCs), CRC antigen-specifically expanded T cells (CTL), and in vitro-expanded NK cells were cultured from patient peripheral blood mononuclear cells (PBMC)...
April 2024: Annals of Coloproctology
#3
REVIEW
Berhane Ghebrehiwet, Michal Zaniewski, Audrey Fernandez, Mathew DiGiovanni, Tiana N Reyes, Ping Ji, Anne G Savitt, Jennie L Williams, Markus A Seeliger, Ellinor I B Peerschke
Understanding at the molecular level of the cell biology of tumors has led to significant treatment advances in the past. Despite such advances however, development of therapy resistance and tumor recurrence are still unresolved major challenges. This therefore underscores the need to identify novel tumor targets and develop corresponding therapies to supplement existing biologic and cytotoxic approaches so that a deeper and more sustained treatment responses could be achieved. The complement system is emerging as a potential novel target for cancer therapy...
2024: Frontiers in Immunology
#4
JOURNAL ARTICLE
Wout De Wispelaere, Daniela Annibali, Sandra Tuyaerts, Julie Messiaen, Asier Antoranz, Gautam Shankar, Nikolina Dubroja, Alejandro Herreros-Pomares, Regina E M Baiden-Amissah, Marie-Pauline Orban, Marcello Delfini, Emanuele Berardi, Thomas Van Brussel, Rogier Schepers, Gino Philips, Bram Boeckx, Maria Francesca Baietti, Luigi Congedo, Kiave Yune HoWangYin, Emilie Bayon, Anne-Sophie Van Rompuy, Eleonora Leucci, Sebastien P Tabruyn, Francesca Bosisio, Massimiliano Mazzone, Diether Lambrechts, Frédéric Amant
BACKGROUND: Uterine leiomyosarcomas (uLMS) are aggressive tumours with poor prognosis and limited treatment options. Although immune checkpoint blockade (ICB) has proven effective in some 'challenging-to-treat' cancers, clinical trials showed that uLMS do not respond to ICB. Emerging evidence suggests that aberrant PI3K/mTOR signalling can drive resistance to ICB. We therefore explored the relevance of the PI3K/mTOR pathway for ICB treatment in uLMS and explored pharmacological inhibition of this pathway to sensitise these tumours to ICB...
May 2024: Clinical and Translational Medicine
#5
REVIEW
Shiva Alipour, Amirhossein Mardi, Neda Shajari, Tohid Kazemi, Mohammad Reza Sadeghi, Javad Ahmadian Heris, Javad Masoumi, Behzad Baradaran
Proper and functional immune response requires a complex interaction between innate and adaptive immune cells, which dendritic cells (DCs) are the primary actors in this coordination as professional antigen-presenting cells. DCs are armed with numerous pattern recognition receptors (PRRs) such as nucleotide-binding and oligomerization domain-like receptors (NLRs) like NLRP3, which influence the development of their activation state upon sensation of ligands. NLRP3 is a crucial component of the immune system for protection against tumors and infectious agents, because its activation leads to the assembly of inflammasomes that cause the formation of active caspase-1 and stimulate the maturation and release of proinflammatory cytokines...
May 4, 2024: Life Sciences
#6
JOURNAL ARTICLE
Peng Bao, Hui-Yun Gu, Yuan-Cheng Jiang, Jia-Wei Wang, Meng Wu, Aixi Yu, Zhenlin Zhong, Xian-Zheng Zhang
One key challenge in postoperative glioblastoma immunotherapy is to guarantee a potent and durable T-cell response, which is restricted by the immunosuppressive microenvironment within the lymph nodes (LNs). Here, we develop an in situ sprayed exosome-cross-linked gel that acts as an artificial LN structure to directly activate the tumor-infiltrating T cells for prevention of glioma recurrence. Briefly, this gel is generated by a bio-orthogonal reaction between azide-modified chimeric exosomes and alkyne-modified alginate polymers...
May 6, 2024: ACS Nano
#7
JOURNAL ARTICLE
Chao Gao, Yuwen Zeng, Linyu Zhang, Jianze Wang, Xiujie Yang, Kui Li, He Ren, Zhaofei Liu
The combination of radiotherapy (RT) and immunotherapy shows promise in improving the clinical treatment of solid tumors; however, it faces challenges of low response rates and systemic toxicity. Herein, an implantable alginate/collagen hydrogel encapsulating C-C motif ligand 21 (CCL21)-expressing dendritic cells (CCL21-DCs@gel) was developed to potentiate the systemic antitumor effects of RT. The hydrogel functioned as a suitable reservoir for in vivo culture and proliferation of CCL21-DCs, thereby enabling sustained CCL21 release...
May 6, 2024: Nano Letters
#8
JOURNAL ARTICLE
Lin Liu, Huali Lei, Guanghui Hou, Lin Zhang, Youdong Chen, Yujie Lu, Zifan Pei, Jun Ge, Jie Wu, Jinhua Zhou, Liang Cheng
The immunosuppressive microenvironment of cervical cancer significantly hampers the effectiveness of immunotherapy. Herein, PEGylated manganese-doped calcium sulfide nanoparticles (MCSP) were developed to effectively enhance the antitumor immune response of the cervical cancer through gas-amplified metalloimmunotherapy with dual activation of pyroptosis and STING pathway. The bioactive MCSP exhibited the ability to rapidly release Ca2+ , Mn2+ , and H2 S in response to the tumor microenvironment. H2 S disrupted the calcium buffer system of cancer cells by interfering with the oxidative phosphorylation pathway, leading to calcium overload-triggered pyroptosis...
May 6, 2024: ACS Nano
#9
JOURNAL ARTICLE
Zhian Chen, Di Zhang, Huilin Huang, Jian Chen, Zhenhao Li, Yanfeng Hu, Ruiyuan Liu
Photothermal therapy has emerged as a promising approach for cancer treatment, which can cause ferroptosis to enhance immunotherapeutic efficacy. However, excessively generated immunogenicity will induce serious inflammatory response syndrome, resulting in a discounted therapeutic effect. Herein, a kind of NIR absorption small organic chromophore nanoparticles (TTHM NPs) with high photothermal conversion efficiency (68.33%) is developed, which can induce mitochondria dysfunction, generate mitochondrial superoxide, and following ferroptosis...
May 6, 2024: Small
#10
Elnaz Amanzadeh Jajin, Saeed Oraee Yazdani, Alireza Zali, Abolghasem Esmaeili
BACKGROUND: Malignant gliomas are known with poor prognosis and low rate of survival among brain tumors. Resection surgery is followed by chemotherapy and radiotherapy in treatment of gliomas which is known as the conventional treatment. However, this treatment method results in low survival rate. Vaccination has been suggested as a type of immunotherapy to increase survival rate of glioma patients. Different types of vaccines have been developed that are mainly classified in two groups including peptide vaccines and cell-based vaccines...
2024: Oncology Reviews
#11
JOURNAL ARTICLE
Zihan Deng, Binghui Li, Muyang Yang, Lisen Lu, Xiujuan Shi, Jonathan F Lovell, Xiantao Zeng, Weidong Hu, Honglin Jin
Immunogenic cell death (ICD) plays a crucial role in triggering the antitumor immune response in the tumor microenvironment (TME). Recently, considerable attention has been dedicated to ferroptosis, a type of ICD that is induced by intracellular iron and has been demonstrated to change the immune desert status of the TME. However, among cancers that are characterized by an immune desert, such as prostate cancer, strategies for inducing high levels of ferroptosis remain limited. Radiated tumor cell-derived microparticles (RMPs) are radiotherapy mimetics that have been shown to activate the cGAS-STING pathway, induce tumor cell ferroptosis, and inhibit M2 macrophage polarization...
May 5, 2024: Journal of Nanobiotechnology
#12
JOURNAL ARTICLE
JieYu Li, WanSong Lin, TianYing Huang, MingShui Chen, QiaoYan Lin
Determining the appropriate source of antigens for optimal antigen presentation to T cells is a major challenge in designing dendritic cell (DC) -based therapeutic strategies against hepatocellular carcinoma (HCC). Tumor-derived exosomes (Tex) express a wide range of tumor antigens, making them a promising source of antigens for DC vaccines. As reported, the exosomes secreted by tumor cells can inhibit the antitumor function of immune cells. In this study, we transfected hepatocellular carcinoma cells with Rab27a to enhance the yield of exosomes, which were characterized using transmission electron microscopy and Western blot analysis...
May 2, 2024: Experimental Cell Research
#13
JOURNAL ARTICLE
Dianlong Jia, Shiqi Zhao, Huimin Liu, Xinyu Zhan, Zhongxia Zhou, Mingjia Lv, Xiufeng Tang, Wen Guo, Hui Li, Lilan Sun, Yidong Zhong, Baoqing Tian, Dandan Yuan, Xiaohui Tang, Qing Fan
In clinical practice, tumor-targeting diagnosis and immunotherapy against programmed death ligand 1 (PD-L1) have a significant impact. In this research, a PD-L1-antagonistic affibody dimer (ZPD-L1 ) was successfully prepared through Escherichia coli expression system, and conjugated with the photosensitizer of ICG via N-hydroxysuccinimide (NHS) ester to develop a novel tumor-targeting agent (ICG-ZPD-L1 ) for both tumor imaging diagnosis and photothermal-immunotherapy simultaneously. In vitro, ZPD-L1 could specifically bind to PD-L1-positive LLC and MC38 tumor cells, and ICG-ZPD-L1 -mediated photothermal therapy (PTT) also showed excellent phototoxicity to these tumor cells...
May 2, 2024: International Journal of Biological Macromolecules
#14
JOURNAL ARTICLE
Matteo Tanzi, Enrica Montini, Agnese Rumolo, Antonia Moretta, Patrizia Comoli, Gloria Acquafredda, Jessica Rotella, Gloria Taurino, Francesca Compagno, Francesco Delle Cave, Cesare Perotti, Gian Luigi Marseglia, Marco Zecca, Daniela Montagna
BACKGROUND AIMS: Somatic cell therapy based on the infusion of donor-derived cytotoxic T lymphocytes (CTL) able to recognize patients' leukemia blasts (LB) is a promising approach to control leukemia relapse after allogeneic HSCT. The success of this approach strongly depends on the ex vivo generation of high-quality donor-derived anti-leukemia CTL in compliance with Good Manufacturing Practices (GMP). We previously described a procedure for generating large numbers of donor-derived anti-leukemia CTL through stimulation of CD8-enriched lymphocytes with dendritic cells (DCs) pulsed with apoptotic LB in the presence of interleukin (IL)-12, IL-7 and IL-15...
April 20, 2024: Cytotherapy
#15
JOURNAL ARTICLE
Yu-Li Lo, Ching-Yao Li, Tsui-Fen Chou, Ching-Ping Yang, Li-Ling Wu, Chun-Jung Chen, Yih-Hsin Chang
Pancreatic ductal adenocarcinoma (PDAC) has an extremely devastating nature with poor prognosis and increasing incidence, making it a formidable challenge in the global fight against cancer-related mortality. In this innovative preclinical investigation, the VCP/p97 inhibitor CB-5083 (CB), miR-142, a PD-L1 inhibitor, and immunoadjuvant resiquimod (R848; R) were synergistically encapsulated in solid lipid nanoparticles (SLNs). These SLNs demonstrated features of peptides targeting PD-L1, EGFR, and the endoplasmic reticulum, enclosed in a pH-responsive polyglutamic (PGA)-polyethylene glycol (PEG) shell...
May 2, 2024: Biomedicine & Pharmacotherapy
#16
JOURNAL ARTICLE
Hector R Mendez-Gomez, Anna DeVries, Paul Castillo, Christina von Roemeling, Sadeem Qdaisat, Brian D Stover, Chao Xie, Frances Weidert, Chong Zhao, Rachel Moor, Ruixuan Liu, Dhruvkumar Soni, Elizabeth Ogando-Rivas, Jonathan Chardon-Robles, James McGuiness, Dingpeng Zhang, Michael C Chung, Christiano Marconi, Stephen Michel, Arnav Barpujari, Gabriel W Jobin, Nagheme Thomas, Xiaojie Ma, Yodarlynis Campaneria, Adam Grippin, Aida Karachi, Derek Li, Bikash Sahay, Leighton Elliott, Timothy P Foster, Kirsten E Coleman, Rowan J Milner, W Gregory Sawyer, John A Ligon, Eugenio Simon, Brian Cleaver, Kristine Wynne, Marcia Hodik, Annette M Molinaro, Juan Guan, Patrick Kellish, Andria Doty, Ji-Hyun Lee, Tara Massini, Jesse L Kresak, Jianping Huang, Eugene I Hwang, Cassie Kline, Sheila Carrera-Justiz, Maryam Rahman, Sebastian Gatica, Sabine Mueller, Michael Prados, Ashley P Ghiaseddin, Natalie L Silver, Duane A Mitchell, Elias J Sayour
Cancer immunotherapy remains limited by poor antigenicity and a regulatory tumor microenvironment (TME). Here, we create "onion-like" multi-lamellar RNA lipid particle aggregates (LPAs) to substantially enhance the payload packaging and immunogenicity of tumor mRNA antigens. Unlike current mRNA vaccine designs that rely on payload packaging into nanoparticle cores for Toll-like receptor engagement in immune cells, systemically administered RNA-LPAs activate RIG-I in stromal cells, eliciting massive cytokine/chemokine response and dendritic cell/lymphocyte trafficking that provokes cancer immunogenicity and mediates rejection of both early- and late-stage murine tumor models...
April 26, 2024: Cell
#17
REVIEW
Eslam E Saad, Rachel Michel, Mostafa A Borahay
PURPOSE OF REVIEW: Since obesity is a major risk factor for many different types of cancer, examining one of the most closely associated comorbidities, such as hypercholesterolemia, is crucial to understanding how obesity causes cancer. Hypercholesterolemia is usually associated with many cardiovascular complications such as hypertension, angina, and atherosclerosis. In addition, cholesterol may be a major factor in increasing cancer risk. Cancer patients who received statins, an anti-hypercholesteremic medicine, demonstrated improved prognosis possibly through its effect on tumor proliferation, apoptosis, and oxidative stress...
May 2, 2024: Current Nutrition Reports
#18
JOURNAL ARTICLE
Jing Zhang, Yuanwei Pan, Lujie Liu, Yangtao Xu, Chenchen Zhao, Wei Liu, Lang Rao
Immune checkpoint blockade (ICB) has brought tremendous clinical progress, but its therapeutic outcome can be limited due to insufficient activation of dendritic cells (DCs) and insufficient infiltration of cytotoxic T lymphocytes (CTLs). Evoking immunogenic cell death (ICD) is one promising strategy to promote DC maturation and elicit T-cell immunity, whereas low levels of ICD induction of solid tumors restrict durable antitumor efficacy. Herein, we report a genetically edited cell membrane-coated cascade nanozyme (gCM@MnAu) for enhanced cancer immunotherapy by inducing ICD and activating the stimulator of the interferon genes (STING) pathway...
May 2, 2024: ACS Nano
#19
JOURNAL ARTICLE
Daping Xie, Congwei Han, Chonghao Chen, Zhencheng Liao, Senio Campos de Souza, Yiming Niu, João F Mano, Lei Dong, Chunming Wang
Cancer vaccination holds great promise for cancer treatment, but its effectiveness is hindered by suboptimal activation of CD8+ cytotoxic T lymphocytes, which are potent effectors to mediate anti-tumor immune responses. A possible solution is to switch antigen-presenting cells to present tumor antigens via the major histocompatibility complex class I (MHC-I) to CD8+ T cells - a process known as cross-presentation. To achieve this goal, we develop a three-dimensional (3D) scaffold vaccine to promote antigen cross-presentation by persisted toll-like receptor-2 (TLR2) activation after one injection...
July 2024: Bioactive Materials
#20
JOURNAL ARTICLE
Aoxing Chen, Junmeng Zhu, Rui Liu, Yi Mei, Lin Li, Yue Fan, Yaohua Ke, Baorui Liu, Qin Liu
Engineered bacteria have shown great potential in cancer immunotherapy by dynamically releasing therapeutic payloads and inducing sustained antitumor immune response with the crosstalk of immune cells. In previous studies, FOLactis was designed, which could secret an encoded fusion protein of Fms-related tyrosine kinase 3 ligand and co-stimulator OX40 ligand, leading to remarkable tumor suppression and exerting an abscopal effect by intratumoral injection. However, it is difficult for intratumoral administration of FOLactis in solid tumors with firm texture or high internal pressure...
July 2024: Bioactive Materials
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
